PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

Not Applicable

Recruiting

Conditions: ALK+ Non-Small-Cell Lung Carcinoma

Interventions: Drug: Lorlatinib

First Posted Date: 2024-07-05

Last Posted Date: 2025-03-25

Lead Sponsor: Pfizer

Target Recruit Count: 90

Registration Number: NCT06487078

Locations: 🇫🇷
Institut Godinot, Reims Cedex, France

SPECIAL INVESTIGATION FOR ABRYSVO IN PREGNANT WOMEN AND INFANTS

Active, not recruiting

Conditions: Respiratory Tract Infection

Interventions: Biological: RSVpreF vaccine

First Posted Date: 2024-07-01

Last Posted Date: 2025-05-22

Lead Sponsor: Pfizer

Target Recruit Count: 490

Registration Number: NCT06482099

Locations: 🇯🇵
Pfizer, Tokyo, Japan

Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.

Active, not recruiting

Conditions: Relapsed and Refractory Multiple Myeloma (RRMM)

First Posted Date: 2024-06-28

Last Posted Date: 2025-06-06

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT06479954

Locations: 🇯🇵
Pfizer, Tokyo, Japan

A Study to Learn About the Safety of BESPONSA Injection in Pediatric Patients With Acute Lymphocytic Leukemia.

Active, not recruiting

Conditions: Acute Lymphocytic Leukemia

First Posted Date: 2024-06-26

Last Posted Date: 2025-05-21

Lead Sponsor: Pfizer

Target Recruit Count: 3

Registration Number: NCT06476665

Locations: 🇯🇵
Pfizer, Tokyo, Japan

A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.

Phase 3

Completed

Conditions: Respiratory Syncytial Virus (RSV)

Interventions: Biological: RSVpreF MDV
Biological: RSVpreF SDV

First Posted Date: 2024-06-25

Last Posted Date: 2024-10-07

Lead Sponsor: Pfizer

Target Recruit Count: 452

Registration Number: NCT06473519

Locations: 🇺🇸
Clinical Research Prime, Idaho Falls, Idaho, United States
🇺🇸
Headlands Research - Detroit, Southfield, Michigan, United States
🇺🇸
Clinical Trials of Texas, LLC dba Flourish Research, San Antonio, Texas, United States

and more 4 locations

A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.

Completed

Conditions: Migraine

First Posted Date: 2024-06-21

Last Posted Date: 2025-03-30

Lead Sponsor: Pfizer

Target Recruit Count: 342

Registration Number: NCT06467370

Locations: 🇺🇸
Pfizer, New York, New York, United States

A Study to Learn How Different Forms of The Study Medicine Called Phenytoin Are Taken up Into the Blood in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Phenytoin (Ascoli)
Drug: Phenytoin (Vega Baja)

First Posted Date: 2024-06-20

Last Posted Date: 2024-10-08

Lead Sponsor: Pfizer

Target Recruit Count: 35

Registration Number: NCT06466473

Locations: 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States

A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: PF-07220060
Drug: letrozole

First Posted Date: 2024-06-18

Last Posted Date: 2024-11-19

Lead Sponsor: Pfizer

Target Recruit Count: 118

Registration Number: NCT06465368

Locations: 🇨🇳
Mackay Memorial Hospital, Taipei, Taiwan
🇨🇳
Chang Gung Medical Foundation-Linkou Branch, Taoyuan, Taiwan
🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

and more 25 locations

A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)

Phase 2

Recruiting

Conditions: Gram-negative Bacterial Infection

First Posted Date: 2024-06-17

Last Posted Date: 2025-06-06

Lead Sponsor: Pfizer

Target Recruit Count: 48

Registration Number: NCT06462235

Locations: 🇺🇸
Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
Norton Children's Hospital, Louisville, Kentucky, United States

and more 16 locations

Description of Relugolix Use in Patients With Prostate Cancer Within the VHA

Completed

Conditions: Prostate Cancer

Interventions: Drug: Relugolix

First Posted Date: 2024-06-17

Last Posted Date: 2025-02-17

Lead Sponsor: Pfizer

Target Recruit Count: 500

Registration Number: NCT06462014

Locations: 🇺🇸
Pfizer, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy